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Monta, Matsudo, Matsumiya (left to right)doi:10.1016/j.jtcvs.2005.05.016Objectives: We sought to elucidate the incidence and timing of myocardial recovery
in patients with idiopathic dilated cardiomyopathy during prolonged support with a
left ventricular assist system and to characterize the factors influencing this phe-
nomenon.
Methods: Since 2000, 11 patients (mean age, 27.9 years) with end-stage heart failure
caused by dilated cardiomyopathy were supported with a left ventricular assist
system for more than 6 months. All patients had aggressive pharmacologic treat-
ment, including -blockers, together with unloading by means of a left ventricular
assist system.
Results: During 239 to 663 days (mean, 453 days) of left ventricular assist system
support, 5 patients had significant recovery of cardiac function and successfully
underwent left ventricular assist system removal. All of these patients have re-
mained in New York Heart Association class 1 during 8 to 29 months of follow-up.
The improvement of left ventricular function started at various times. In particular,
2 of 5 recovered patients started to show improvement after 1 year of left ventricular
assist system support. The myocardial fibrosis did not resolve but rather worsened
in all patients during left ventricular assist system support. However, myocardial
fibrosis was less severe in the recovered group (17.7%  8.2% at left ventricular
assist system implantation vs 20.1%  5.2% at explantation) in comparison with
that in the nonrecovered group (30.5% 13.2% vs 48.4% 5.1%) both before and
after use of the left ventricular assist system.
Conclusion: Patients with severe congestive heart failure caused by dilated cardio-
myopathy have a good chance of myocardial recovery and successful explantation
of the left ventricular assist system. A relatively slow response of myocardial
recovery during prolonged left ventricular assist system support was demonstrated
in some patients. A lesser degree of fibrotic changes in the left ventricle was
predictive of recovery.
Recent reports have shown that idiopathic dilated cardiomyopathy (DCM),which had been considered irreversible, can be restored to almost normalcardiac function during support with a left ventricular assist system (LVAS),
and recovery can be sustained for years after the explantation of the LVAS.1-3
Despite basic studies demonstrating the favorable effects of unloading of the left
ventricle,4-7 many questions still exist in clinical application of this strategy: Who
can experience recovery and who cannot? What is the difference between these 2
groups? What percentage of patients have meaningful recovery? How long should
one wait before abandoning the expectation of recovery? Past reports included
patients with congestive heart failure (CHF) of many causes and those who were
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period,8 and thus it has been hard to answer most of these
questions.
In Japan we could restart heart transplantation in 1999
under new legislation.9 However, donor supply is still se-
verely limited, and many patients require an LVAS while
awaiting heart transplantation. This severe shortage of or-
gan donors has resulted in a situation in which prolonged
mechanical support exceeding 1 year is routinely required
before heart transplantation.10 This gave us a unique oppor-
tunity to observe and evaluate the patients supported with an
LVAS for a more prolonged period than in other countries.
In this study we have analyzed the incidence and timing of
myocardial recovery during this prolonged LVAS support
and the factors influencing this phenomenon.
Patients and Methods
Patients
Ethical committee approval was obtained for this retrospective
study, and informed consent was given by all the patients. From
August 2000 to the end of 2003, a total of 13 patients with
end-stage heart failure caused by DCM received the LVAS. The
diagnosis of DCM based on histologic analyses, and no patient had
signs of myocarditis. One patient died of massive cerebral bleeding
at the second week from the operation, and another died of cerebral
infarction at the third month. The other 11 patients survived for
more than 6 months and underwent the serial evaluation of native
cardiac function. Ten patients were male, and 1 patient was female.
Age ranged from 15 to 38 years, with a mean of 27.9  7.6 years.
Preoperatively, all the patients had New York Heart Association
class IV CHF symptoms and were dependent on inotropic support.
All patients were taking angiotensin-converting enzyme inhibitors
(ACEIs), diuretics, and spironolactone. -Blockers were initiated
in all patients, but 6 patients could not tolerate them because of
hemodynamic deterioration or worsening of bronchial asthma. The
indication for LVAS implantation was chronic progression of CHF
in all the patients and not acute deterioration in stable CHF. Two
patients required extracorporeal life support, 4 required an intra-
aortic balloon pump, and 5 were dependent on a ventilator. The
history of heart failure ranged from 3 to 120 months, with a mean
of 34  34.6 months.
Operations
The type of device used was the HeartMate-IP (Thermo Cardio-
systems, Inc, Woburn, Mass) in 8 patients, the HeartMate-VE in 2
patients, and the Novacor (Baxter Healthcare Corp, Novacor Div,
Oakland, Calif) in 1 patient. The operation was performed as
previously described. During cardiopulmonary bypass, apical cor-
ing and mitral annuloplasty (MAP), if indicated, were performed
during cardioplegic cardiac arrest, and other procedures followed
on the beating heart. MAP was performed to prevent recurrence of
mitral regurgitation and to maintain left ventricular (LV) perfor-
mance after possible LVAS removal. Simultaneous procedures
performed during the operations were MAP with a 26-mm Cos-
grove ring (Edwards Lifesciences, Irvine, Calif) for more than
mild mitral regurgitation in 4 patients, tricuspid annuloplasty with
the DeVega technique for more than mild tricuspid regurgitation in
700 The Journal of Thoracic and Cardiovascular Surgery ● Sept2 patients, and implantation of a temporary right ventricular assist
system in 1 patient.
Heart Failure Treatment
As soon as the patient’s general condition was stabilized and organ
dysfunction recovered, medical treatments for heart failure were
initiated. This regimen included ACEIs, digoxin, spironolactone,
and a -blocker (carvedilol). Carvedilol was initiated at a dosage
of 2.5 mg/d and doubled every week until a dosage of 20 to 40
mg/d was reached. No patients were indicated for biventricular
pacing. One patient had episodes of sustained ventricular tachy-
cardia and received an automatic implantable cardioverter-defibril-
lator during LVAS support.
Assessment of Cardiac Function and LVAS Weaning
Protocol
Echocardiography was performed every week in the first month
and biweekly thereafter. Brain natriuretic peptide (BNP) levels
were measured every week in the first month and monthly there-
after. After 3 months of entire unloading by LVAS, an LVAS
off-test was performed in case echocardiography showed improve-
ment of LV end-diastolic diameter of less than 55 mm and LV
ejection fraction (LVEF) of more than 45% with a regularly
running pump. The LVAS off-test was conducted as follows.
During systemic heparinization (3 mg/kg), the LVAS pump rate
was gradually decreased and stopped completely. After 10 minutes
of heart beating without mechanical support, hemodynamic pa-
rameters and LV function were assessed by using a Swan-Ganz
catheter and echocardiography. Then dobutamine was loaded up to
30 g · kg1 · min1, and cardiac function was assessed. Weaning
of LVAS was initiated in patients who had no deterioration of the
hemodynamic and echocardiographic LV function during the
LVAS halt and their further improvement with the increasing dose
of dobutamine. The pump rate was set at the fixed mode and was
decreased 10 pulses/min every week until the minimum pump rate
of 50 pulses/min was reached. During this period, the BNP level
was monitored every week. Unless the increase of BNP level
occurred and the repeated LVAS off-test showed deterioration of
LV function, explantation of the LVAS was performed.
LVAS Explantation and Follow-up
The LVAS was removed without cardiopulmonary bypass by
using a modification of the method described by Hetzer and
colleagues.11 In brief, a median skin incision over the pump pocket
was extended toward the left anterior thoracotomy at the fifth or
sixth intercostal space. The sternum was not split. During systemic
heparinization, the pump was stopped, and the outflow and inflow
conduits were clamped, cut, and oversewn. The apical cannula and
most of the outflow graft were left in place. As soon as the
endotracheal tube was extubated, heart failure medication was
restarted. Cardiac function was assessed serially by means of
echocardiography.
Histologic Analyses
Myocardial specimens were obtained at the time of LVAS implan-
tation and then at the time of heart transplantation or autopsy. At
LVAS explantation, myocardium was obtained with a biopsy
needle from the anterior wall of the left ventricle. These specimens
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Pwere fixed in 10% formalin, embedded in paraffin, and sectioned
at a thickness of 5 m. The specimens were stained with hema-
toxylin and eosin for light microscopic examination. The fibrosis
area was calculated with the use of an image-analysis system
(SPICCA II; Olympus, Tokyo, Japan), and the percentage of
interstitial fibrosis was calculated as the average of the ratios of the
fibrosis area to the total area from the 10 random sections.
Statistical Analysis
The quantitative data are presented as means standard deviation.
Comparisons among groups were calculated by using the Mann-
Whitney U test and the Fisher exact test for nonparametric data.
Results
The patients were categorized into the following 2 groups
depending on their changes in cardiac function and subse-
quent clinical course (Tables 1 and 2). The recovery group
includes the 5 patients who had significant recovery of
cardiac function and underwent successful LVAS explanta-
tion after support periods of 239 to 662 days. They all are
doing well and have been in New York Heart Association
class 1 during 8 to 29 months of follow-up, with almost
normal echocardiographic parameters and BNP levels. The
nonrecovery group includes the 6 patients who had inade-
TABLE 1. Patients and follow-up data: Recovery group
(n  5)
Age/sex
Days on
LVAS
Recovery
course
Days after
LVAS
explantation
LVEF*
(%)
LVDd*
(mm)
BNP*
(pg/mL)
33/M 460 Early 895 56 58 19.1
34/M 435 Early 799 60 55 25.6
31/M 239 Early 757 48 52 11.2
20/M 350 Late 554 53 51 53.6
15/M 662 Late 248 54 50 32.4
LVAS, Left ventricular assist system; LVEF, left ventricular ejection fraction;
LVDd, left ventricular diastolic dimension; BNP, brain natriuretic peptide.
*Data evaluated at the most recent outpatient clinic visit.
TABLE 2. Patients and follow-up data: Nonrecovery group
(n  6)
Age/sex
Days on
LVAS Prognosis Cause of death
21/F 515 Heart
transplantation
27/M 642 Death Cerebral
infarction
37/M 392 Death Infection
38/M 244 Death Infection
30/M 628 Death Infection
21/M 395 Death InfectionLVAS, Left ventricular assist system.
The Journal of Thoraciquate improvement of echocardiographic parameters during
LVAS full support or hemodynamic deterioration or poor
response to dobutamine stress during the LVAS off-test and
could not undergo LVAS removal. Heart transplantation
was performed after 515 days of LVAS support in 1 patient,
and 5 patients died of infectious or cerebrovascular compli-
cations 244 to 642 days after the LVAS implantation.
Table 3 shows the characteristics of the patients before
LVAS implantation in each group. There was no significant
difference except in duration of heart failure symptoms
before LVAS implantation, which was significantly longer
in the nonrecovery group. -Blocker therapy was tolerated
only in 1 (20%) patient of the recovery group compared
with two thirds of the patients in the nonrecovery group,
although this did not reach statistical significance. The
changes of echocardiographic parameters after LVAS im-
plantation were divided in the following 3 patterns (Figure
1). In all the nonrecovered patients, LVEF remained less
than 40% throughout the course. The recovered patients
were divided in 2 subgroups. Three patients had rapid
improvement of LVEF in the first 3 months after LVAS
TABLE 3. Characteristics of patients
Recovery
group (n  5)
Nonrecovery
group (n  5)
P
value
Age (y) 26.6 8.5 29.0  7.4 NS
Sex (M:F) 5:0 5:1 NS
Duration of CHF (mo) 10.2 8.0 53.8 36.2 .028
-Blocker
intolerance
4/5 (80%) 2/6 (33.3%) NS
LVEF (%) 17.4 4.8 15.8  5.4 NS
LVDd (mm) 71.4 5.7 73.3  7.2 NS
CI (L · min1 · m2) 1.99 0.6 1.60  0.5 NS
MPAP (mm Hg) 38.2 4.9 39.7  10.7 NS
Preoperative support
Inotropes 5/5 (100%) 6/6 (100%) NS
Ventilator 3/5 (60%) 2/6 (33.3%) NS
IABP 3/5 (60%) 1/6 (16.7%) NS
ECLS 1/5 (20%) 1/6 (16.7%) NS
Concomitant
procedure
MAP 1/5 (20%) 2/6 (33.3%) NS
TAP 0/5 (0%) 1/6 (16.6%) NS
RVAS 0/5 (0%) 1/6 (16.6%) NS
LVAS support (d) 429.4 156.5 470.3 155.8 NS
LVAS off-test*
MPAP (mm Hg) 15.6 4.72 33.5 14.8 NS
CI (L · min1 · m2) 3.27 0.44 2.11 0.22 NS
CHF, Congestive heart failure; LVEF, left ventricular ejection fraction; LVDd,
left ventricular diastolic dimension; CI, cardiac index; MPAP, mean pul-
monary artery pressure; IABP, intra-aortic balloon pump; ECLS, extracor-
poreal life support; MAP, mitral annuloplasty; TAP, tricuspid annuloplasty;
RVAS, right ventricular assist system; LVAS, left ventricular assist system;
NS, not significant. *Measured with a Swan-Ganz catheter while the LVAS
was turned off in 5 recovery and 3 nonrecovery group patients.
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patients had almost the same LVEF as the nonrecovered
group for 1 year, but gradual improvement took place af-
terward and eventually reached the criteria for LVAS re-
moval (late recovery group). The change in serum BNP
level followed the reverse pattern of the change in LVEF in
each group (Figure 2). In the 3 patients of the early recovery
group, serum BNP level demonstrated a rapid decrease to
the normal value in the first 3 months. The other 8 patients
did not reach the normal value in 1 year. Although the
nonrecovery group had an increase of BNP after 1 year, the
other 2 patients in the late recovery group demonstrated a
decrease to the normal value after 1 year. Histologically, the
percentage of fibrosis at the time of LVAS implantation
ranged between 8.1% and 51.6%. The patients in the recov-
ered group had significantly lower percentages of fibrosis
(17.7%  8.2%) than those in the nonrecovered group
(30.5%  13.2%). When we look at the change of fibrosis
during LVAS support, myocardial fibrosis progressed in all
the patients, including those in the recovery group. How-
ever, the percentage of fibrosis at LVAS explantation wors-
ened more significantly in the nonrecovered group (48.4%
 5.1%) than in the recovered group (20.1%  5.2%,
Figure 3).
Discussion
Reverse remodeling of a failed left ventricle by means of
Figure 1. Change of LVEF. Changes of echocardiographic param-
eters after LVAS implantation were divided in 3 patterns. In all the
nonrecovered patients, LVEF remained less than 40% throughout
the course. Three patients had rapid improvement of LVEF in the
first 3 months after LVAS implantation (early recovery group). Two
patients had gradual improvement after 1 year and eventually
reached the criteria for LVAS removal (late recovery group).
Diamonds, Early recovery (n  3); squares, late recovery (n  2);
triangles, nonrecovery (n  6).mechanical unloading with LVAS is attracting increasing
702 The Journal of Thoracic and Cardiovascular Surgery ● Septinterest.12 However, many questions remain, especially re-
garding its clinical appearance and the mechanisms in-
volved at the cell and tissue levels.13 Although the clinical
observations vary in each report, relatively common find-
Figure 3. Change of myocardial fibrosis during LVAS support. The
recovered patients had a significantly lower percentage of fibro-
sis (17.7%  8.2%) than the nonrecovered group (30.5%  13.2%)
at LVAS implantation. In all patients, including the recovery
group, myocardial fibrosis progressed during LVAS support. The
percentage of fibrosis at the time of LVAS explantation was
significantly higher in the nonrecovered group (48.4%  5.1%)
than in the recovered group (20.1%  5.2%). Squares, Recovered;
Figure 2. Change of BNP. The change of serum BNP level fol-
lowed the reverse pattern of the change in LVEF. In the early
recovery group serum BNP level demonstrated rapid decrease to
the normal level in the first 3 months. Although the nonrecovery
group had an increase of BNP after 1 year, the 2 patients in the
late recovery group demonstrated a decrease to the normal level
after 1 year. Diamonds, Early recovery (n  3); squares, late
recovery (n  2); triangles, nonrecovery (n  6).triangles, nonrecovered.
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Pings are that recovery more likely occurs in the patients
clinically characterized by younger age, shorter history of
CHF, and application of the apical drainage type of
LVAS.11 However, the incidence of myocardial recovery
during LVAS support is variously reported to be between
4%8 and 33%.3 This discrepancy might have arisen from
many issues. The patient population differed, and aggres-
siveness of pharmacologic treatment during LVAS support
and its regimen, such as the use of 1-blocker14 or 2-
agonist,3 varied. More importantly, the duration of LVAS
support was significantly different because the bridge-to-
transplantation cases were included in most of the past
reports. The time course of recovery of LV function has also
not been clearly understood. Several reports have described
that the early improvement of cardiac function is one of the
predicting factors for successful recovery. Müller and asso-
ciates1 showed that the LV end-diastolic diameter and
LVEF 2 months after LVAS implantation significantly cor-
related with the sustained LV recovery. Sodian and cowork-
ers15 demonstrated that BNP levels at the first week after
LVAS implantation were significantly lower in the recov-
ered patients. These observations partly coincide with our
experience, in which 3 of 5 patients had quick recovery of
LV function in the first 3 months. However, in 2 of 5
recovered patients, the significant recovery of LV function
started after more than 1 year of support. This observation
has been unique in our study. Hetzer and colleagues11 also
described 2 patients who were weaned from LVAS after
more than a year out of 23 patients who underwent LVAS
explantation. However, those patients had marginal LV
function before the explantation, had recurrence of CHF,
and eventually required heart transplantation. They were
clearly different from our patients, who had complete and
sustained recovery. The mechanism of this late recovery is
presently unknown. A prospective study with ACEIs and
-blockers demonstrated that the reverse remodeling pro-
cess continues during 1 year of medical treatment.16 The
multifactorial nature of the remodeling process might cause
those time course differences in each patient.17 LVAS dys-
function negatively affected recovery in 2 patients, who had
late occurrence of inflow valve regurgitation. Right heart
function might also influence the recovery, but no patients
in the present study had signs of right heart failure.
The other significant finding in our study is the important
role of myocardial fibrosis in the functional recovery.
Bruckner and associates18 demonstrated significant correla-
tion between a lesser degree of preexisting fibrosis and
greater improvements of cardiac function during LVAS
support. Our study also showed a lesser degree of preoper-
ative fibrotic change in the recovered ventricle. From our
data, less than 30% of myocardial fibrosis predicts a good
chance of successful weaning from the LVAS. It might be
a reasonable explanation for this phenomenon that the re-
The Journal of Thoracicovered patients deteriorated faster and reached the point
when they required LVAS implantation sooner, and as a
result, the fibrotic change did not progress to the point at
which recovery is impossible.
There are conflicting reports on whether fibrosis
progresses or regresses during LVAS support. Hetzer and
colleagues14 demonstrated improvement of myocardial fi-
brosis during LVAS support in the recovered patients. On
the contrary, there are several reports showing that unload-
ing by the LVAS does not change preexisting fibrotic
change.19 Our histologic analyses showed that the degree of
fibrosis did not regress but rather worsened in most cases,
including in 5 recovered patients, although the progression
was much slower in the recovery group. A possible expla-
nation for this discrepancy can be derived from the differ-
ences in LVAS duration, pharmacologic treatment, and
aggressiveness of the weaning protocol. Li and associates5
showed no change of total collagen content, but reduced
collagen damage manifested as the increased ratio of unde-
natured collagen during LVAS. Not only collagen content
but also its quality can influence the LV function.
Why does cardiac function improve during LVAS sup-
port? There are reports demonstrating improvement of neu-
rohormonal status,20 calcium handling in the sarcoplasmic
reticulum,21 and myocardial response to adrenergic stimu-
lus6 during LVAS support by hemodynamic normalization
and unloading of the left ventricle. Sympathetic nerve over-
stimulation has one of the most significant correlations with
the progression of CHF. -Blocker therapy is now one of
the most reliable modalities for heart failure treatment.
Some of our patients, especially in the recovered group,
were in severe heart failure and could not tolerate -blocker
therapy preoperatively. The LVAS enabled -blocker ther-
apy in all the patients, which might have contributed to the
improvement of the sympathetic nerve function. We previ-
ously reported that the LVAS alone did not improve the
sympathetic nerve activity, as assessed on the basis of
iodine 125–labeled metaiodobenzylguanidine.22 The recov-
ered patient in the present series showed serial improvement
of the sympathetic nerve activity assessed by means of
iodine 125–labeled metaiodobenzylguanidine (data not
shown). The theoretic advantages of use of clenbuterol, a
selective 2-agonist, together with a 1-antagonist have
been described in several articles. It might become a useful
adjunctive treatment to hasten recovery, although a larger
multi-institutional study would be needed before its wider
application.
Clinical Implications
Our data showed that in selected patients with DCM, wean-
ing from the LVAS is a possible option. This phenomenon
might occur more frequently than we previously expected,
especially when the patients are supported for a prolonged
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evaluation are used. If we can determine those patients at an
early stage after implantation, we can save the unnecessary
heart transplantation and thus use the limited supply of
donor hearts more effectively. From our experience and
other recent reports, the degree of myocardial fibrosis is one
of the key factors for predicting successful weaning from
the LVAS. If a patient with DCM has less than 30% of
fibrosis in the LV apex, possible recovery can be observed.
If a more reliably used long-term device becomes available
in the near future, those patients can be observed for at least
6 months to 1 year and then evaluated for recovery or
transplantation candidacy.
Limitations
There are several limitations to this study. First, the number
of the patients included in the study is small, and therefore
selection bias is possible. In particular, our patient popula-
tion was younger than that seen in past reports. The type of
device might be another factor influencing myocardial re-
covery because the unloading effect is different in each
device. All of our patients supported for a prolonged period
received implantable pulsatile devices, which can achieve
powerful unloading. In addition, ischemic cardiomyopathy
was not included, and some of the patients had a relatively
short history of CHF. These might have influenced the
relatively high incidence of recovery in our patients. Our
histologic analysis was performed with a myocardial spec-
imen from the LV apex. Although there is a concern of
regional heterogeneity of fibrotic change, most of the past
studies have also used myocardium from the same area,
which is the only available sample in the pre-LVAS
situation.
Conclusions
Patients with severe CHF caused by DCM have a good
chance of myocardial recovery and successful explantation
of the LVAS. A relatively slow response of myocardial
recovery during prolonged LVAS support was demon-
strated in some patients. A lesser degree of fibrotic changes
in the left ventricle was predictive of recovery.
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